Publish date:

March 13-19


A table in the March 17 story,

Value Funds Rack Up Double-Digit Gains on Dow Rise, mistakenly showed that 20 value funds posted double-digit percentage gains on Thursday. In fact, the gains came over two days, Wednesday and Thursday. (

corrected March 17


The March 17 Stock Strategies column,

Get Two Companies (Or More) For the Price of One, mischaracterized the nature of a trade show presentation by photonic switch maker


, describing it as "longer on bikini-clad women than breakthrough technology." In fact, the women involved in the presentation were dressed in lab coats, not bikinis, a company spokeswoman says. (

corrected March 17


The March 15 Evening Update,

Phillips Buys Arco's Alaskan Biz for $7 Billion, incorrectly reported

Electro Scientific's

(ESIO:Nasdaq) third-quarter 1999 earnings as 26 cents a share. In fact, the company earned a pro forma 12 cents a share in the third quarter. (

corrected March 16


The March 13 Evening Update,

Four IPOs Price in Evening Action, incorrectly reported that

Zany Brainy

(ZANY:Nasdaq) posted fourth-quarter earnings of 55 cents a share, down from the year-ago report of $1.09 a share. In fact, the company's pro forma earnings for the fourth quarter of 1998 were 39 cents, meaning the fourth-quarter 1999 results were an improvement on the year-ago profit. (

corrected March 16


The Dec. 21 Herb on TheStreet column,

One Backdoor (Uh, Cheap) Way Into Hot Stocks, incorrectly identified

IPC Communications

(IPI:Amex) as IPC Holdings and mistakenly reported that its shares trade on the


. In fact, IPC Communications shares trade on the


. (

corrected March 16


The March 14

Nightwatch incorrectly identified


(MSEL:Nasdaq) as a reseller of

Sun Microsystems

(SUNW:Nasdaq) products. In fact, Merisel distributes products from 500 manufacturers, including Sun. (

corrected March 16


The March 15 SuperModels column,

A Well-Bred Genetics Play With Maximum Potential, incorrectly reported that biotech concern


was sold to

Glaxo Wellcome

TST Recommends

(GLX:NYSE ADR) in 1995. The sale took place in 1994. Also, the story incorrectly reported that another biotech concern,


(AZA:NYSE), was sold to

Abbott Laboratories

(ABT:NYSE) in 1999 for $7.3 billion. In fact, that proposed deal wasn't completed. (

corrected March 16


A March 15 story,

Retail Investors Looking to Get Fat on the Krispy Kreme IPO, misidentified a senior research analyst at the

Hennsler Equity Fund

. He is Walter Stackow, not William Stackow. (

corrected March 15


A March 2 story,

Five Things You Need to See Before Buying Bank Stocks, mistakenly reported that

National City's

(NCC:NYSE) stock was down 75% from the beginning of 1999 at the time of publication. That figure failed to take into account a stock split in July 1999. Taking the split into account, National City's stock was off 47% at the time of publication. (

corrected March 15


The March 13 Tax Forum,

Get the Most Mileage From Your Auto Deductions, incorrectly reported that if you lease your car you can use only the standard-rate method of determining your deductible auto expenses. In fact, you can use either the standard-rate or the actual-cost method. If you use the standard-rate method, you must continue using that method for the length of the auto's lease.

Also, if you own your car, you aren't required to use the standard-rate method in the first year, as we reported. But if you use the actual-cost method in the first year you won't be able to switch to the standard-rate method in subsequent years. (

corrected March 14


A March 13 story,

Why a Lucent Bear Has Turned Bullish, incorrectly reported that


(LU:NYSE) in January predicted earnings would be weak for its fiscal second quarter ending in March. In fact, Lucent warned at that time of weak results for its first quarter, ended Dec. 31. (

corrected March 14


The March 10 Midday Movers,

Rambus Soaring on Split News and Dial Lower on Earnings Warning, incorrectly reported that

SG Cowen

initiated coverage of

Exodus Communications

(EXDS:Nasdaq) with a buy rating. In fact, the stock was given a rating of strong buy. (

corrected March 13


A March 9 Silicon Babylon column,

Cannonade Shakes Snowbird Sleepers, quoted

Critical Path

(CPTH:Nasdaq) CEO Doug Hickey saying the company would provide calendaring and guaranteed delivery for all of


(T:NYSE) customers. In fact, Critical Path will provide calendaring and guaranteed delivery solutions to AT&T's B2B portals.

(corrected March 10)